This year, 40 women students are participating, selected through a rigorous process evaluating academic merit, research interest, and socio-economic background
Lupin and Zentiva sign license and supply agreement for commercializing Certolizumab
Addresses brain metastases harboring BRCA1/2 and/or HRR alterations—an area of high unmet need
Approval based on NIAGARA Phase III trial results which showed a 32% reduction in the risk of recurrence and a 25% reduction in the risk of death for the Imfinzi regimen vs. neoadjuvant chemotherapy alone
ARGX-119 is the sixth molecule developed through our Immunology Innovation Program to show proof-of-concept
Surpassing 1,000 Company Owned Company Operated stores
The acquisition of Pivya is an important step in Alembic’s ability to provide branded pharmaceutical product to the US Healthcare market
The site, spanning approximately 25,000 square meters, is expected to commence operations by the end of 2025
Opaganib has shown potential in enhancing ARPI treatment by blocking multiple enzymes involved in cancer cell survival.
Enhance strategies to drive sustainability, global Reach and digital transformation for a trillion-dollar future
Subscribe To Our Newsletter & Stay Updated
